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Serotonin, the ‘‘happiness’’ neurotransmitter, has complex cardiovas-
cular effects. Serotonin-related mechanisms have been involved in
valvular heart disease (VHD) in animals and humans in the setting
of carcinoid tumors, fenfluramine-phentermine, and ergot alkaloids
intake. Selective serotonin reuptake inhibitors (SSRIs) and serotonin
and noradrenaline reuptake inhibitors (SNRIs) are the most widely
prescribed antidepressants. An association between heart valve le-
sions and use of serotonergic antidepressants is controversial. This
case of a relatively young woman supports a potential causal relation-
ship between SSRI use and VHD.CASE PRESENTATION
A 41-year-old woman was referred for peripartum hypertension for
which she had been treated with amlodipine for the last 2 weeks
before delivery. The pregnancy and birth were further uncomplicated,
and blood pressure was successfully managed with amlodipine and ir-
besartan. She had a history of essential arterial hypertension, major
depression, anxiety, and obsessive-compulsive disorder for which
she had been treated with psychotherapy and medication. Since
2010, she had been being treated with escitalopram 20 mg and later
on switched to sertraline up to 100 mg, nortriptyline 50 mg, aripipra-
zole 5 mg, trazodone 100 mg, and clonazepam 0.5 mg.
Being a dance teacher, she had no complaints about and reported
no cardiorespiratory symptoms or exercise intolerance. Physical ex-
amination showed a mentally and physically healthy woman, blood
pressure of 126/80 mm Hg, a regular pulse of 72 bpm, normal
head and neck examination, normal heart and lung auscultation, ten-
der abdomen with no hepatosplenomegaly, and no peripheral
cyanosis or edema. The electrocardiogram showed sinus rhythm
with pronounced P waves, QRSmorphology consistent with left ante-
rior hemiblock, and normal repolarization.f Cardiology (L.D., F.T., T.D.B.), Department of Cardiac
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/j.case.2020.11.003Echocardiographic examination showed a nondilated, concentric
remodeled left ventricle with preserved ejection fraction. Mild left-
sided valve disease was observed, with thickened mitral and aortic
valve leaflets, both showing mild regurgitation. The right ventricle
(RV) was dilated (RV end-diastolic diameter/left ventricle end-dia-
stolic diameter ratio of 1) and showed diastolic septal D shaping, sug-
gestive of RV volume overload. Right ventricular function was
preserved, and no regional RV dysfunction or wall abnormalities
were observed. The right atrium was severely dilated (52 mL/m2).
A severe, central tricuspid valve regurgitation (TR) with a dense, trian-
gular continuous-wave Doppler signal (dagger-shaped Doppler pro-
file) was present. Structurally, the subvalvular and valvular apparatus
had a thickened and shortened appearance. The tricuspid leaflets
showed restrictive motion, with the septal leaflet almost completely
immobilized due to leaflet thickening and chordal retraction causing
a large leaflet coaptation defect (Figure 1).
An estimation of right ventricular pressure based on Bernoulli’s
principle was normal (20mmHg), and the central venous pressure es-
timate was also normal. Conditions that may cause RV volume over-
load (such as severe pulmonary regurgitation, high cardiac output, or
cardiac or extracardiac left-to-right shunts) were excluded by echocar-
diography and right heart catheterization, which showed a normal car-
diac output (4.9 L/minute), normal pulmonary pressures (mean
pulmonary artery pressure 15 mm Hg), and normal pulmonary capil-
lary wedge pressure of 1 mm Hg.
As the TR seemed to be a primary or structural TR, several potential
causes for degenerative TR were assessed. No leaflet vegetations were
observed, and blood analysis showed no abnormalities (normal
C-reactive protein, white blood cell counts, and eosinophil counts).
Rheumatic valve disease, characterized by diffuse fibrous thickening
of the leaflets, rather results in fusion of the commissures and in
tricuspid valve (TV) stenosis, which was not present in our case.
There were no features of Ebstein’s anomaly or congenital TV
dysplasia. Autoimmune disease and vasculitis, rarely causing valvulop-
athy, were excluded through laboratory testing (rheumatoid factor
<11.30 U/mL, antinuclear antibodies negative, antineutrophil cyto-
plasmic antibody fluorescence negative). Importantly, the patient de-
nied (former) use of known valvulopathic drugs such as ergotamine,
methysergide, cabergoline, pergolide, (dex)fenfluramine, or ben-
fluorex. The patient had no symptoms of carcinoid syndrome, and uri-
nary 5-hydroxyindoleacetic acid levels (5.1 mg/24 h) and serum
chromogranin A (123 mg/L) were within normal ranges. Finally,
abdominal ultrasound revealed no abnormalities; in particular, no
liver abnormalities were present.
Cardiac magnetic resonance imaging confirmed moderate RV dila-
tation with preserved RV ejection fraction. Flow mapping analysis
yielded a TR volume of 54 mL with a regurgitant fraction of 44%.
Anomalous pulmonary venous drainage was excluded, and no
endomyocardial fibrosis was observed.1
Figure 1 Echocardiography (apical four-chamber view in systole) showed a moderately dilated RV and severely dilated right atrium.
The subvalvular and valvular apparatus had a thickened and shortened appearance. The leaflets were restrictive due to chordal retrac-
tion causing noncoaptation (A). A severe TR was present (B).
Figure 2 The free edges of the tricuspid valve were thickened
and appeared as sclerotic plaque. Papillary muscles were big
2 Defruyt et al CASE: Cardiovascular Imaging Case Reports
- 2020Because of intrinsic structural valve disease with severe TR and sec-
ondary right ventricular dilatation, the patient underwent minimal
invasive surgery of the TV. The TV was tricuspid with the anterior
and posterior leaflet having almost equal size. On gross examination,
the free edges of the TV showed clear thickening (Figure 2). Papillary
muscles were prominent with shortened chordae, and the septal
leaflet was retracted. Because of the valve destruction, TV replace-
ment with a bioprosthesis was performed.
Microscopic analysis of the excised anterior tricuspid leaflet
showed proliferation of myofibroblasts embedded in a collagenous
and myxoid-enriched stroma. Inflammatory infiltrates, calcifications,
and neovascularization were not observed in the specimen.
Endocardial deposition of a ‘‘stuck-on’’ carcinoid-like plaque along
the ventricular aspect was noted (Figure 3). Histopathological findings
were compatible with features of carcinoid-like VHD.with very short chordae, and the septal leaflet was retracted.
Figure 3 Histopathology of the anterior leaflet of the tricuspid
valve: collagenous and myxoid stroma, with proliferation of
myofibroblasts and the presence of a nodular, sclerotic plaque
(hematoxylin and eosin staining).DISCUSSION
Severe structural TV regurgitation was diagnosed in this patient.
Based on extensive investigations to rule out other causes of valve dis-
ease, we favor the diagnosis of drug-induced VHD (DI-VHD), related
to prolonged intake of SSRIs. Although the exact pathophysiological
mechanism through which these pharmaceuticals may cause
morphological and functional changes of heart valves is not fully un-
derstood, it has been observed that DI-VHD is reminiscent of carci-
noid heart disease.1-3 Because of the similarities between DI-VHD
and carcinoid heart disease, it was discovered that DI-VHD is medi-
ated through 5-hydroxytryptamine 2b receptor signaling pathways.1,2
Serotonergic agents or their metabolites that specifically interact with
this receptor may therefore cause carcinoid-like VHD. Yet the associ-
ation between SSRI/SNRIs and VHD is controversial, and the path-
ophysiological mechanisms that may underpin a causal relationship
remain enigmatic. Concerning SSRIs, limited and small case-control
studies have been reported. Mast et al.4 reported a retrospective
drug safety evaluation and failed to establish an association between
SSRIs and heart valve regurgitation. A prospective French multicenter
study did not support a valvulopathic role of SSRI in patients exposed
to benfluorex.5 De Backer et al.6 retrospectively investigated the risk
of VHD in relation to the use of SSRIs. They did observe an associa-
tion between the use of serotonergic antidepressants and a dose-dependent increased rate of valvular regurgitation. In general, the dif-
ficulties in interpreting the controversial results in DI-VHD relate to
the inherent risk of bias and confounding due to methodological is-
sues in study design, type of populations studied, low numbers of
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time, unblinded echocardiographic assessments, and variable defini-
tions of echocardiography-assessed DI-VHD.7
Even if SSRIs or SNRIs truly cause DI-VHD, significant valve
dysfunction may be a rare event notwithstanding the large number
of patients treated with SSRIs or SNRIs. Rare events are (statistically)
challenging with respect to establishing a correct cause-consequence
relationship, as other concomitant causes of valve disease may be
more prevalent in these patients. Therefore, exclusion of other poten-
tial causes for the current degenerative valve phenotype is mandatory.
Based on (1) the exclusion of other potential causes for the TV pheno-
type, (2) the similar degenerative lesions observed on the mitral and
aortic valve in our patient, and (3) the observation of stuck-on plaques
on histopathological examination, we provide evidence for a SSRI/
SNRI-induced valvulopathy. Admittedly, our case report triggered
scrutiny on whether the histopathological identification of a ‘‘carci-
noid-like plaque’’ is the pathognomonic lesion to diagnose seroto-
nergic DI-VHD. Indeed, reporting bias in previous studies
considering serotonergic-mediated valve disease may have neglected
the occurrence of such degenerative lesions in other causes or path-
ways of alternative degenerative valve disease (without performing
histologic examinations of resected valves in these cases). Therefore,
further research on this issuemay be required, and vigilance for poten-
tial DI-VHD in clinical practice remains necessary.
CONCLUSION
Serotonin-related mechanisms have been involved in VHD, as
observed in the setting of carcinoid tumors, fenfluramine-phenter-
mine, and ergot alkaloids intake. The association between SSRIs/
SNRIs and VHD, however, remains controversial, and only limited
case-control studies have been reported. Through extensivediagnostic workup, this case provides evidence for SSRI-induced val-
vulopathy. The final course of developing disease might be an inter-
play between the drug’s pharmacological properties and a person’s
intrinsic genetic characteristics and environmental factors. This case
report teaches us to maintain vigilance. When initiating drugs that
are known to activate serotonin pathways, a risk-benefit analysis
should be made on an individual basis, and clinical-echocardiographic
surveillance during the treatment course is advised.REFERENCES
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